Tier 2 — strong

Quercetin Intake and Absolute Telomere Length in Patients with Type 2 Diabetes Mellitus: Novel Findings from a Randomized Controlled Before-and-After Study

Aikaterini E Mantadaki, Stella Baliou, Manolis Linardakis, Elena Vakonaki, Manolis N Tzatzarakis, Aristides Tsatsakis, Emmanouil K Symvoulakis
Pharmaceuticals (Basel, Switzerland) 2024 17(9):1136

Bibliography

PubMed
PMID 39338301
PubMed Central
PMC11434860
DOI
10.3390/ph17091136
Funding
Reported funding/support: This research received no external funding.
Competing interests
Reported disclosure: The authors declare no conflicts of interest.

Study snapshot

DesignSecondary telomere analysis of a randomized open-label trial
ModelHuman intervention research
Sample82 participants with type 2 diabetes provided telomere samples; 100 initially randomized
InterventionQuercetin 500 mg/day plus usual care versus usual care
DurationTwo 12-week treatment periods separated by 8-week washout
EndpointsSenescence-related measurements

What the study showed, in plain terms

Published in 2024, this source examined senescence and longevity. Design: Secondary telomere analysis of a randomized open-label trial. Sample/model: 82 participants with type 2 diabetes provided telomere samples; 100 initially randomized. The exposure or intervention was Quercetin 500 mg/day plus usual care versus usual care. Follow-up or treatment period: Two 12-week treatment periods separated by 8-week washout.

The quercetin arm showed a favorable whole-blood telomere-length association after adjustment.

Subset analysis from the same cohort as the main diabetes report. A blood telomere measurement does not establish slower aging or longer life.

Continue with Quercetin Data Center

For topic-level interpretation, read Is Quercetin a Senolytic? Human Evidence vs Longevity Claims. This is a related guide; the citation panel separately identifies articles that directly cite this paper.

Key findings

  • The quercetin arm showed a favorable whole-blood telomere-length association after adjustment.
  • The recorded outcome domains were Senescence-related measurements.
  • The result applies to the tested exposure: Quercetin 500 mg/day plus usual care versus usual care; Two 12-week treatment periods separated by 8-week washout.

What this study can and cannot tell us

  • Subset analysis from the same cohort as the main diabetes report. A blood telomere measurement does not establish slower aging or longer life.
  • Without a sufficiently blinded concurrent control, time effects, expectations, co-interventions and regression toward the mean can explain part of an apparent improvement.
  • Companion or correction records are linked below. They should not be counted automatically as independent replications; see the individual source notes for the relationship.
  • Source basis: Source check: accessible full text and indexed metadata. Missing method details, funding information or participant denominators are not inferred.

Related papers in the corpus

Tier 2
Benefits of Quercetin on Glycated Hemoglobin, Blood Pressure, PiKo-6 Readings, Night-Time Sleep, Anxiety, and Quality of Life in Patients with Type 2 Diabetes Mellitus: A Randomized Controlled Trial
Aikaterini E Mantadaki et al. · Journal of clinical medicine · 2024
Tier 2
The Impact of Three-Month Quercetin Intake on Quality of Life and Anxiety in Patients With Type II Diabetes Mellitus: An Early Data Analysis From a Randomized Controlled Trial
Aikaterini E Mantadaki et al. · Cureus · 2024
Tier 2
Senolytics dasatinib and quercetin in metabolic dysfunction-associated steatohepatitis: a proof-of-principle randomized, controlled trial
Mijra Koning et al. · Nature metabolism · 2026
Tier 2
Evaluation of exploratory fluid biomarkers from a phase 1 senolytic trial in mild Alzheimer's disease
Valentina R Garbarino et al. · Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2025
Tier 2
Effects of intermittent senolytic therapy on bone metabolism in postmenopausal women: a phase 2 randomized controlled trial
Joshua N Farr et al. · Nature medicine · 2024

Citation network

Articles citing this research paper

1 article

Biohack Blueprint analyses that reference this study in their evidence base.

Editorial review

Reviewed by the Biohack Blueprint research team

Last verified

Dr. Khaled Mahmoud, MBBChCritical Care Medicine, Longevity Science & Editorial Direction Dr. Amr Yasser, PhDCardiometabolic, Musculoskeletal, Gut & Bioavailability Dr. Abdulla Mostafa, PhDCellular Senescence, Neurological, Mitochondrial & Brain-Ageing Biology